ZHEJIANG JIANFENG GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.77 CNY | -1.57% |
|
-2.23% | -20.63% |
| May. 28 | China Approves Jianfeng's Marketing Application for Antibiotic Raw Material | MT |
| May. 14 | Zhejiang Jianfeng's Pharmaceutical Unit Gets Nod to Market Anti-Tumor Drug | MT |
| Sales 2022 | 3.56B 492M | Sales 2023 | 2.89B 400M | Capitalization | 3.8B 525M |
|---|---|---|---|---|---|
| Net income 2022 | 288M 39.77M | Net income 2023 | 93M 12.84M | EV / Sales 2022 | 1.26 x |
| Net Debt 2022 | 109M 15.07M | Net Debt 2023 | 333M 45.93M | EV / Sales 2023 | 1.43 x |
| P/E ratio 2022 |
15.2
x | P/E ratio 2023 |
40.9
x | Employees | 1,978 |
| Yield 2022 |
1.18% | Yield 2023 |
0.9% | Free-Float | 76.01% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.57% | ||
| 1 week | -2.23% | ||
| Current month | -0.34% | ||
| 1 month | -0.34% | ||
| 3 months | -7.10% | ||
| 6 months | -21.70% | ||
| Current year | -20.63% |
1 week
8.76
9.03
1 month
8.769.35
Current year
7.9411.24
1 year
7.9412.15
3 years
7.9425.65
5 years
7.9425.65
10 years
7.9425.65
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Hong Yu
CEO | Chief Executive Officer | 58 | 08-09-04 |
Xiao Long Lan
DFI | Director of Finance/CFO | 51 | 14-11-11 |
Jin Long Huang
BRD | Director/Board Member | 59 | 08-09-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Meng Jiang
CHM | Chairman | 60 | 07-08-16 |
Jian Hong Yu
CEO | Chief Executive Officer | 58 | 08-09-04 |
Xu Ping Qin
BRD | Director/Board Member | 61 | 11-11-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-30 | 8.77 | -1.57% | 1,828,621 |
| 24-05-29 | 8.91 | +0.22% | 1,042,000 |
| 24-05-28 | 8.89 | -1.22% | 1,308,000 |
| 24-05-27 | 9 | +0.33% | 2,261,279 |
| 24-05-24 | 8.97 | 0.00% | 1,918,900 |
End-of-day quote Shanghai S.E., May 29, 2024
More quotes
ZHE JIANG JIAN FENG GROUP CO., LTD is a China-based company, principally engaged in the manufacture and distribution of cement and pharmaceuticals. The Company mainly conducts its cement business in Hubei Province, Yunnan Province, Zhejiang Province and Guangxi Province. The Company provides pharmaceuticals, including anti-infective drugs, antipyretic and analgesic drugs, drugs for cardiovascular system diseases, drugs for diabetes mellitus, bulk drugs, intermediates and over the counter (OTC) products. The Company is also engaged in the provision of health products, and the manufacture and distribution of cables. The Company conducts its business in domestic markets.
Sector
Construction Materials
Calendar
2024-09-01
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.63% | 417M | |
| +19.05% | 49.49B | |
| +7.21% | 16.83B | |
| -17.17% | 13.4B | |
| -13.86% | 10.85B | |
| +40.52% | 8B | |
| +11.36% | 7.92B | |
| -5.74% | 7.64B | |
| -9.58% | 7.23B | |
| +15.16% | 5.63B |
- Stock Market
- Equities
- 600668 Stock
